People · Operator
Named in public records as an officer, director or promoter · active 2022–2025 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Mediar Therapeutics, Inc. | — | Biotechnology | Series C | $127.9M | $194.8M | 2022 |
Simon Sturge at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Simon Sturge on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Peter Parker | 1 | 6 |
| Meredith Fisher | 1 | 6 |
| Michael Baran | 1 | 4 |
| Brian Hubbard | 1 | 4 |
| Nandita Shangari | 1 | 4 |
| David De Graaf | 1 | 3 |
| Allan Marchington | 1 | 3 |
| Andreas Jurgeit | 1 | 2 |
| Marie-Claire Peakman | 1 | 2 |
| Cassidy Blundell | 1 | 2 |
| Rahul Ballal | 1 | 2 |
| Stacey Brenner | 1 | 1 |
| Adam Cotton | 1 | 1 |
| Bharat Srinivasa | 1 | 1 |
| Maina Bhaman | 1 | 1 |
| Anja Konig | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.